SCHEMBL16661263

SCHEMBL16661263

CSc1n[nH]c(-c2ccc(Br)cc2Cl)n1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DCUN1D1 Q96GG9 8/20 0.48
▸ ALPL P05186 2/20 0.47
▸ GRK6 P43250 4/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GPR55 Q9Y2T6 1/20 0.40
▸ PTGES O14684 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ ALPG P10696 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20428838 0.82 DCUN1D1 (0.48) DCUN1D1ALPLGRK6KDM4EPOLB
SCHEMBL16661004 0.82 DCUN1D1 (0.48) DCUN1D1ALPLGRK6KDM4EPOLB
SCHEMBL16661200 0.75 DCUN1D1 (0.42) DCUN1D1ALPLKDM4EPOLBNPC1
SCHEMBL16661193 0.74 DCUN1D1 (0.69) DCUN1D1ALPLGRK6KDM4EPOLB
SCHEMBL16787885 0.70 PTGES (0.39) KDM4ELMNAHTTKMT2APTGES
SCHEMBL16661001 0.70 DCUN1D1 (0.49) DCUN1D1ALPLGRK6KDM4EPOLB
SCHEMBL20265414 0.69 PIM1 (0.41) PTGES
SCHEMBL8158453 0.68 DCUN1D1 (0.74) DCUN1D1ALPLKDM4EPOLBNPC1
SCHEMBL16661030 0.67 DCUN1D1 (0.49) DCUN1D1ALPLGRK6KDM4EPOLB
SCHEMBL25957505 0.67 DCUN1D1 (0.66) DCUN1D1ALPLGRK6KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10308636-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-04 — — US disclosed
EP-2862856-B1 IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2018-08-01 — — EP disclosed
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-23 — — US disclosed
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-23 — — US disclosed
US-9546155-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-17 — — US disclosed
US-9546155-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-17 — — US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 — — US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 — — US disclosed
EP-2862856-A1 AROMATIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-04-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 DCUN1D1 276/4885ALPL 4178/4885GRK6 1934/4885
US-10308636-B2 Aromatic heterocyclic compound GPR119, NR0B1, BET1 DCUN1D1 276/4885ALPL 4178/4885GRK6 1934/4885
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 DCUN1D1 276/4885ALPL 4178/4885GRK6 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback